NATCO Pharma shares sinks 28% in 2 days on Q3 earnings miss, brokerage downgrade

NATCO Pharma shares tumbled 10% on Friday, extending a two-day slump to 28% after weak Q3 results and a target price cut by Nuvama. Profit fell 37.75% YoY, impacted by lower formulations exports and Agrochem weakness. Despite a strong U.S. pipeline and cash reserves, analysts remain cautious on near-term growth. NATCO Pharma shares tumbled 10% on Friday, extending a two-day slump to 28% after weak Q3 results and a target price cut by Nuvama. Profit fell 37.75% YoY, impacted by lower formulations exports and Agrochem weakness. Despite a strong U.S. pipeline and cash reserves, analysts remain cautious on near-term growth.  Economic Times